Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지

Genotoxicity Tests on Hyrubicin ID6105, a Novel Anthracycline Anticancer Agent

새로운 Anthracycline계 항암제 Hyrubicin ID6105에 대한 유전독성연구

  • Published : 2002.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

The genotoxic potential of Hyrubicin lD6105, a novel anthracycline anticancer agent, was examined on bacterial mutagenicity, mammalian cell chromosome aberration and mouse micronucleus tests. In mutagenicity (Ames') test, Salmonella typhimurium strain TA98, TA100, TA1535 and TA1537, and Escherichia coli WP2uvrA- were treated with ID6105 at doses of 312.5, 625, 1,250, 2,500 and 5,000 $\mu\textrm{g}$/ plate with or without a metabolic activation system (S9 mix). Interestingly, ID6105 significantly enhanced the number of revertant colonies of TA98 strain at all dose levels used, in the presence or absence of S9 mix, without affecting other strains of S. typhimurium and E. coli. In chromosome aberration test using cultured chinese hamster lung fibroblasts, ID6105 (1.25, 2.5 and 5 $\mu\textrm{g}$/ml) did not increase the number of aberrant cells, compared with vehicle control. in the presence or absence of S9 mix. In addition, ID6105 treatment (2.5, 5 and 10 mg/kg) did not induce micronucleated polychromatic erythrocytes in mice. Taken together, it is suggested that ID6105 might not affect chromosome integrity in mammalian system in vitro and in vivo, although it may induce frame shift mutation of specific bacterial strain such os S. typhimurium TA98.

Keywords

References

  1. Mut. Res. v.31 Methods for detecting carcinogens and mutagens with the salmonella/mammalian-microsome mutagenecity test Ames,B.M.;McCann,J.;Yamasaki,E. https://doi.org/10.1016/0165-1161(75)90046-1
  2. Goodman and Gilman's the Pharmacological Basis of Therapeutics(8th Ed.) Antineoplastic agents Calabresi,P.;Chabner,B.A.
  3. Cancer principle and Practice of Oncology(3rd Ed.) Clinical pharmaclolgy of cancer chemotherapy
  4. Life Sci. v.25 New development on the mechanisms of action of antineoplastic drugs Donehower,R.C.;Myers,C.E.;Chabner,B.A. https://doi.org/10.1016/0024-3205(79)90483-1
  5. Cytogenetics v.3 An air-drying method for meiotic preparations from mammalian tests Evans,E.P.;Breckon,G.;Ford,E. https://doi.org/10.1159/000129818
  6. Toxicol. Appl. Pharmacol. v.80 The embryotoxicity of adriamycin in rat embryos in vitro Fantel,A.G.;Greenway,J.C.;Juchau,M.R. https://doi.org/10.1016/0041-008X(85)90110-3
  7. Mut. Res. v.223 Difference between imtraperitoneal and oral gavage application in the micronucleus testing Hayashi,M.;Sutou,S.;Shimida,H.;Sato,S.;Sasaki,Y.F.;Wakada,A. https://doi.org/10.1016/0165-1218(89)90081-5
  8. Mut. Res. v.48 Chromosome test with 134 compounds on Chinese hamster cell in vitro-a screening for chemical carcinogens Ishidate,M.Jr;Odashima,S. https://doi.org/10.1016/0027-5107(77)90177-4
  9. Mut. Res. v.113 Revised methods for the Salmonella mutagenicity test Maron,D.M.;Ames,B.N. https://doi.org/10.1016/0165-1161(83)90010-9
  10. J. Immunol. Methods v.65 Rapid colorimetric assay for cellular growth and survival:application to proliferation and cytotoxicity assays Mosmann,T. https://doi.org/10.1016/0022-1759(83)90303-4
  11. Mut. Res. v.31 The micronucleus test Schmid,W. https://doi.org/10.1016/0165-1161(75)90058-8
  12. 한국응용약물학회지 v.1 새로운 항암성 항생물질 DA-125의 심장독성에 대한 평가 백남기;안병옥;이순복;김원배;양준익;渡邊俊彦
  13. 신기능생물소재기술개발사업 보고서 신규항암제 Hyrubicin 개발 연구 강종구;정연복;장호송
  14. 식품의약품안정청고시 제 1999-61호 의약품 등의 독성시험기준 식품의약품안전청